Agilent Technologies Inc. has announced the expansion of their strategic collaboration with Monash University in Malaysia to establish a state-of-the-art MUMPMP-Agilent BioDiscovery Hub aimed at accelerating regional biotechnology research and innovation.
The new Memorandum of Understanding (MOU) was signed as part of the celebration of their 15-year strategic partnership, underscoring Agilent's continued commitment to advancing high-impact R&D capabilities in fast-growing Asian markets.
Under the renewed agreement, Agilent will place its high-resolution Revident Quadrupole Time of Flight LC/MS systems, coupled with 1290 Infinity III High-Performing LC series, and the next-generation 5977C Gas Chromatography/MSD, at the new hub to support mutually agreed research programs, applications development, workshops, and scientific training. This collaboration is designed to accelerate R&D in both small- and large-molecule analysis, enabling deeper insights across biomedical, pharmaceutical, and molecular biology fields.
"This collaboration reflects Monash University Malaysia's commitment to delivering world-class research infrastructure that advances discovery and benefits our communities. The MUMPMP–Agilent BioDiscovery Hub strengthens Monash's position as a regional leader in proteomics, metabolomics, and biotechnology innovation. By combining Agilent's state-of-the-art technologies with Monash's research excellence and multidisciplinary ecosystem, we are empowering our scientists and partners to drive impactful solutions for Malaysia and the Asia-Pacific region", said Dr Syafiq Asnawi, Senior Lecturer in Biomedical Science and Director of the Department of Molecular Epidemiology & Translational Medicine and the MUM Proteomics & Metabolomics Platform.
